Cell line · CVCL_1639
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Differential Control of Growth and Identity by HNF4α Isoforms in Pancreatic Ductal Adenocarcinoma. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma. | Cells | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. | Front Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. | J Hematol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Non-canonical functions of SNAIL drive context-specific cancer progression. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. | Cell Rep | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1639/papers